← Back to Patent Explorer
US4677121A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of inhibiting muscle protein degradation

Assignee: Johns Hopkins University
•
Filing: 1985-10-31
•
Granted: 1987-06-30
•
Expires: 2005-10-31
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Muscle protein breakdown or degradation may be reduced or inhibited in mammals, particularly humans recovering from surgery or suffering from a muscle wasting disorder, by administering daily doses of alpha-ketoisocaproic acid (ketoleucine) or an appropriate salt of the acid. Seventy millimoles per day of sodium alpha-ketoisocaproate administered for five days after major abdominal surgery was found to significantly reduce urinary 3-methylhistidine/creatinine, which is a measure of muscle protein breakdown, and thereby to improve nitrogen balance.

Inventors

  • 👤 Mackenzie Walser
  • 👤 Daniel G. Sapir
  • 👤 Peter M. Stewart

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 17:22
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 35 words
A method of reducing muscle protein degradation in patients suffering from such degradation comprising administering to said patient an effective amount of a composition consisting essentially of alpha-ketoisocaproic acid or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim 35 words
A method of reducing muscle protein degradation in patients suffering from such degradation comprising administering to said patient an effective amount of a composition consisting essentially of alpha-ketoisocaproic acid or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim 13 words
A method according to claim 1 wherein the patient is recovering from surgery.
Claim 4
Dependent Claim 20 words
A method according to claim 2 wherein sodium alpha-ketoisocaproate is administered in an amount of about 70 millimoles per day.
Claim 5
Dependent Claim 16 words
A method according to claim 1 wherein the patient is suffering from a muscle wasting disorder.
Claim 6
Dependent Claim 15 words
A method according to claim 1 wherein the salt of alpha-ketoisocaproic acid is sodium alpha-ketoisocaproate.
Claim 7
Dependent Claim 20 words
A method according to claim 1 wherein said composition is in the form of a solution which is administered intravenously.
Claim 8
Dependent Claim 32 words
A method according to claim 1 wherein the patient is suffering from a condition or disease where there is a disparity between the rates of muscle protein synthesis and muscle protein degradation.
Claim 9
Dependent Claim 16 words
A method according to claim 7 wherein the patient is suffering from accelerated muscle protein degradation.

References Cited (Backward Citations)

US4100161A Cited
US4100160A Cited
US4100293A Cited
US4228099A Cited
US4320146A Cited
US4296127A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-06-29 1990-12-29 1991-06-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-06-29 1994-12-29 1995-06-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-06-29 1998-12-29 1999-06-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag